Delphi Private Advisors’s GSK GSK Stock Holding History

Delphi Private Advisors’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-1,920	Closed	-$85K	–	100
2017 Q4	$85K	Buy	+1,920	New	+$88.7K	0.21%	46

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Delphi Private Advisors's GSK Position: Q1 2018 in Review

Delphi Private Advisors sold out of GSK (GSK) in Q1 2018, closing a stake of 1,920 shares — an estimated $85K sold.

Delphi Private Advisors first reported a position in GSK in Q4 2017 and held it in 1 quarter. The position peaked at $85K in Q4 2017. 778 funds tracked by Wall St. Rank hold GSK as of Q1 2018.

Delphi Private Advisors reported no remaining GSK position as of Q1 2018 after selling out during the quarter.
Delphi Private Advisors sold 1,920 GSK shares in Q1 2018, an estimated $85K.
Delphi Private Advisors first reported a position in GSK in Q4 2017 and held it in 1 quarter.
Delphi Private Advisors's GSK position peaked at $85K in Q4 2017.
778 funds tracked by Wall St. Rank held GSK as of Q1 2018.

Based on Delphi Private Advisors's 13F filing for Q1 2018, filed 2 May 2018.